Friday, September 19, 2025 2:49:25 PM
You said look at the chart- it’s a piece of shite.”Let’s really look at the chart, and try to make sense of it. Just a few basic TA points to make. There are 3 basic patterns to consider, in all time frames you see these patterns . Upwave, Downwave, and sideways. The predictive models will show mathematic and geometric target zones of pullback/support that “ought to hold “ in an upwave pattern, and the opposite applies in downwave patterns. My basic measurement tool is the Fibonacci retrace, looking at the 50% target zone, but also the 62%. When you measure the entire upwave from let’s say 7 to 14, the 50% retrace will show a target zone around 10.50, to anticipate. The next lower Fib target zone/62% would suggest around 9.65. If you look at the latest major wave pattern, you can see how these target zones came into play.
If I’m watching this Upwave that doubled from 7 to 14, I want to see how it holds support in the major pullback. 11.00 is ok, 10.50/10.30 is ok. Even 9.60 is ok if it holds and begins the next upwave. But If it continues down to lower targets 9.30/9.00 and now 8.50, it’s not a piece of shitt, it’s just losing the technical “upwave” pattern and must be seen as developing some other kind of pattern. And that pattern could be a Range Pattern. The larger chart shows 2 distinct Range patterns. One is from 7 to 14 and back to 7 and back to 14. And the other pattern is a mini version, from 7 to 10 to 7 to 10. It is possible, in a range pattern, that we could see this downwave get taken back to the 7’s again. But right now, it’s bleeding down the target steps, one or two steps at a time , it’s being done carefully, cleverly, to reach their desired target. The 8.50 is a target as is 8.40/8.30 and 8.00 area. And for giggles and fun bottom fishing, I’ll save some dry powder for 7.88. Trading Range Patterns isn’t much different from other types of trading. It’s just a matter of seeing the pattern change happening in a timely way. That pattern started changing when 10 dollars and 9.30 failed to hold and 9.60 became resistance and now this bleeding down isn’t a pullback as much , it’s more of a downwave.
When you now look at the last times it fell into the 7’s, and rallied from the bottom,you see pivots around 7.85/7.70 area, 7.65/ 7.50,/7.25,/ and the 7.16 bottom.
Right now, the 8.50 got hit my stink bids filled,
and now I’ll buy some more closer to 8.00/8.20 next time. Small portions at a time for me.
A Range Pattern is a little bit ugly to see what looked like big bullish upwave from 7 to 14 … that gets sold all the way back down, that never feels very good. But traders don’t mind, you buy at 7 or 8 and sell at the 13 or 14, and then do it again.
Now imagine how remarkable it was, like the holy grail of trading, what K9 John did, buying at 3 dollars, selling at 30, and buying it all back again at 3. 🫡. 🤩
If I’m watching this Upwave that doubled from 7 to 14, I want to see how it holds support in the major pullback. 11.00 is ok, 10.50/10.30 is ok. Even 9.60 is ok if it holds and begins the next upwave. But If it continues down to lower targets 9.30/9.00 and now 8.50, it’s not a piece of shitt, it’s just losing the technical “upwave” pattern and must be seen as developing some other kind of pattern. And that pattern could be a Range Pattern. The larger chart shows 2 distinct Range patterns. One is from 7 to 14 and back to 7 and back to 14. And the other pattern is a mini version, from 7 to 10 to 7 to 10. It is possible, in a range pattern, that we could see this downwave get taken back to the 7’s again. But right now, it’s bleeding down the target steps, one or two steps at a time , it’s being done carefully, cleverly, to reach their desired target. The 8.50 is a target as is 8.40/8.30 and 8.00 area. And for giggles and fun bottom fishing, I’ll save some dry powder for 7.88. Trading Range Patterns isn’t much different from other types of trading. It’s just a matter of seeing the pattern change happening in a timely way. That pattern started changing when 10 dollars and 9.30 failed to hold and 9.60 became resistance and now this bleeding down isn’t a pullback as much , it’s more of a downwave.
When you now look at the last times it fell into the 7’s, and rallied from the bottom,you see pivots around 7.85/7.70 area, 7.65/ 7.50,/7.25,/ and the 7.16 bottom.
Right now, the 8.50 got hit my stink bids filled,
and now I’ll buy some more closer to 8.00/8.20 next time. Small portions at a time for me.
A Range Pattern is a little bit ugly to see what looked like big bullish upwave from 7 to 14 … that gets sold all the way back down, that never feels very good. But traders don’t mind, you buy at 7 or 8 and sell at the 13 or 14, and then do it again.
Now imagine how remarkable it was, like the holy grail of trading, what K9 John did, buying at 3 dollars, selling at 30, and buying it all back again at 3. 🫡. 🤩
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
